Key Drivers
- Liquidity Position
- Leverage Risk
- Support Hold
AIAI Summary
TEM has moved from a speculative AI diagnostics story to a credible operating inflection with revenue beats, raised guidance, and first-time EBITDA/net income positivity, but the investment case now hinges on converting that earnings improvement into positive free cash flow fast enough to justify its premium valuation and offset dilution, leverage, and integration risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Position
- •Leverage Risk
TEM's profitability is improving and liquidity is solid, but persistent cash burn, high leverage, and a premium valuation still make the stock a cautious hold.
Valuation: TEM still trades at a demanding sales and book multiple, leaving limited upside unless execution continues to improve.
Price Behavior
Key Price Behavior Insights:
- •Support Hold
- •Resistance Cap
- •Recovery Fade
TEM recovered sharply from a late-July low but is now consolidating just above $52 support, with $54.29-$55.69 resistance capping the move and a breakdown risking a slide back into the mid-to-upper $40s.
Sharp drop to $42.69 followed by a strong rebound to $55.69 before easing back
Sentiment & News
Key News Insights:
- •Raised Guidance
- •Pricing Upside
- •Valuation Pressure
Tempus AI is showing stronger growth momentum from better-than-expected results, raised guidance, and FDA-linked pricing gains, but valuation, cash burn, and Personalis-related dilution remain key investor concerns.
The news is modestly positive for Tempus AI's growth outlook, but the stock may stay volatile as investors balance improving fundamentals against execution and valuation risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings